Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 6/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2510786 | 0.91 | PRKAA2 (0.41) | PRKAA2EPHX2HRH3ADRB2 | |
| SCHEMBL12199842 | 0.91 | PRKAA2 (0.39) | PRKAA2KDM1AHRH3CYP2D6KCNH2 | |
| SCHEMBL1036731 | 0.91 | MAOA (0.39) | CETPPRKAA2EPHX2GPBAR1ADRB2 | |
| SCHEMBL1037082 | 0.91 | ADRB2 (0.37) | CETPPRKAA2CYP2D6CYP3A4ADRB2 | |
| SCHEMBL2507385 | 0.83 | PRKAA2 (0.55) | CETPPRKAA2EPHX2CYP3A4 | |
| SCHEMBL1034060 | 0.83 | ADRB2 (0.39) | PRKAA2KCNH2ADRB2 | |
| SCHEMBL2505967 | 0.82 | ADRB2 (0.36) | PRKAA2ADRB2MDM2 | |
| SCHEMBL12199849 | 0.82 | PRKAA2 (0.37) | PRKAA2HRH3 | |
| SCHEMBL12199833 | 0.82 | ALDH1A1 (0.38) | HRH3 | |
| SCHEMBL12199829 | 0.81 | MAOA (0.44) | PRKAA2GPBAR1HRH3CYP3A4FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785449-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | claimed |
| US-20130023660-A1 | Carboxamide Compounds and Methods for Using the Same | RIGEL PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | claimed |
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | US | claimed |
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9409884-B2 | 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9353111-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353111-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20160122321-A1 | Carboxamide Compounds and Methods for Using the Same | MIDCAP FINANCIAL TRUST | 2016-05-05 | — | — | US | disclosed |
| US-20160122321-A1 | Carboxamide Compounds and Methods for Using the Same | MIDCAP FINANCIAL TRUST | 2016-05-05 | — | — | US | disclosed |
| US-9255085-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20130023660-A1 | Carboxamide Compounds and Methods for Using the Same | RIGEL PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-8314107-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314107-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314107-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | CS, SHMT2, GOT2 | CETP 2517/4885PRKAA2 413/4885EPHX2 3141/4885 |
| US-20160122321-A1 | Carboxamide Compounds and Methods for Using the Same | PC, AK2, PRKAA2 | CETP 2623/4885PRKAA2 3/4885EPHX2 2893/4885 |
| US-20130023660-A1 | Carboxamide Compounds and Methods for Using the Same | PC, AK2, PRKAA2 | CETP 2623/4885PRKAA2 3/4885EPHX2 2893/4885 |
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | PC, AK2, PRKAA2 | CETP 2623/4885PRKAA2 3/4885EPHX2 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.